Biocryst Pharmaceuticals (BCRX) Amortizatization of Intangibles (2023 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Amortizatization of Intangibles came in at $251000.0 in Q1 2026, up 118.15% YoY from $115059.0 in Q1 2025, and up 123.01% on a QoQ basis from -$1.1 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 4 years of Amortizatization of Intangibles data on file, last reported at $251000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 118.15% year-over-year to $251000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.7 million (up 72.12% YoY) and the FY2025 annual result came in at -$4.3 million, up 62.25% from the prior year.
- Amortizatization of Intangibles climbed to $251000.0 in Q1 2026, from -$1.1 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $251000.0 in Q1 2026 to a low of -$3.5 million in Q2 2024.
- A 4-year average of -$2.0 million and a median of -$2.0 million in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles plunged 129.68% — and 2026, when it soared 118.15%.
- Tracing BCRX's Amortizatization of Intangibles over 4 years: stood at -$3.4 million in 2023, then climbed by 19.98% to -$2.8 million in 2024, then surged by 60.47% to -$1.1 million in 2025, then jumped by 123.01% to $251000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $251000.0 (Q1 2026), -$1.1 million (Q4 2025), and -$707000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | -417,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -417,000.00 |
| Jun 30, 2026 | -417,000.00 |
| Mar 31, 2026 | 251,000.00 |
| Mar 31, 2026 | 251,000.00 |
| Dec 31, 2025 | -1.09 Mn |
| Dec 31, 2025 | -1.09 Mn |
| Sep 30, 2025 | -707,000.00 |
| Sep 30, 2025 | -707,000.00 |
| Jun 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -3.49 Mn |
| Mar 31, 2024 | -3.18 Mn |
| Mar 31, 2024 | -3.18 Mn |